Proxygen

Proxygen is a pioneering startup operating in the pharmaceutical industry, specifically in the realm of targeted protein degradation. This innovative approach to drug development has the potential to revolutionize the way we treat diseases. Traditional drugs often only block specific functions of harmful proteins, but Proxygen's technology, known as molecular glue degraders, can eliminate these proteins entirely. This opens up the possibility of targeting proteins previously considered "undruggable".

Proxygen's business model is centered around the development and identification of these molecular glue degraders. They have developed unique discovery assays, which are tests that allow them to identify and develop new glue degraders at scale. This puts them at the forefront of this new and largely unexplored area of pharmaceuticals.

The company serves a broad market, including scientific institutions and other pharmaceutical companies looking for innovative solutions to disease treatment. They generate revenue through the development and sale of their molecular glue degraders, as well as through partnerships with other entities in the pharmaceutical industry.

Proxygen is based in Vienna, a leading science hub, and has access to a network of high-class science institutions and centers of excellence across Europe and the world. Their interdisciplinary team of scientists is dedicated to changing the way incurable diseases are treated, making them an exciting and promising player in the pharmaceutical industry.

Keywords: Targeted Protein Degradation, Molecular Glue Degraders, Drug Development, Pharmaceutical Industry, Innovative Technology, Disease Treatment, Discovery Assays, Scientific Institutions, Interdisciplinary Team, Vienna Science Hub.